MaxCyte

MaxCyte is a cell-engineering platform company whose Flow Electroporation® technology and ExPERT™ instrument family are used to transfect cells for the discovery, development and manufacture of next-generation cell therapies. Rather than developing therapeutics itself, MaxCyte licenses its instruments and technology and sells consumables to cell-therapy developers, pharmaceutical and biotechnology companies, and academic and translational research centres, and it runs a Strategic Platform License (SPL) program under which partners embed its platform in clinical and commercial manufacturing. A second franchise, SeQure™ Dx, supplies gene-editing risk-assessment assays that screen, nominate and confirm editing outcomes for gene-editing therapeutic developers. Founded in 1999 and headquartered in Rockville, Maryland, the company has supported more than 35 partner-sponsored clinical trials across oncology, central nervous system disorders and rare genetic diseases. On October 14, 2026 MaxCyte reported preliminary third-quarter core business revenue of approximately $8.1 million, up 26% year over year, and raised full-year 2026 revenue guidance to approximately $34 million from a prior $30–32 million range, citing accelerated instrument purchasing by a large customer and a second 2026 SPL milestone.